Prosensa's new board member highlights focus on muscular dystrophy drugs

Today’s announcement from Prosensa that a former CFO of Genzyme will join its supervisory board is a clear sign that the Dutch company best known for a failed late-stage trial in muscular dystrophy may yet give local biotech firm Sarepta Therapeutics a run for its money...